JACKSONVILLE, FL., Nov. 17, 2025 (GLOBE NEWSWIRE) -- LFTD Partners Inc. ("LFTD Partners" or the "Company") (OTCQB: LIFD), the corporate parent of leading hemp, wellness and energy products maker Lifted Made (“Lifted”), today reported its financial results for the third quarter ended September 30, 2025. Financial results are reported in accordance with U.S. generally accepted accounting principles and all currency is in U.S. dollars. Income Statement – Q3 2025 Compared to Q3 2024: Revenue increased 4% to $9, ...

Core Viewpoint - PetMed Express, Inc. has announced preliminary second quarter fiscal year 2026 results, indicating a significant decline in net sales compared to the previous year, and has filed a Notification of Late Filing with the SEC due to delays in filing its Form 10-Q [1][2]. Financial Performance - For the fiscal second quarter ended September 30, 2025, net sales are estimated to range from $43.4 million to $44.5 million, a decrease from $58.0 million in the prior year period [2]. - For the six months ended September 30, 2025, net sales are estimated to range from $94.5 million to $95.6 million, down from $124.3 million in the prior year period [2]. - The company reported $36.1 million in cash and no debt as of September 30, 2025 [4]. Compliance and Regulatory Issues - On November 12, 2025, the company received a notice from Nasdaq indicating non-compliance due to delays in filing its Quarterly Reports for the periods ended June 30, 2025, and September 30, 2025 [5]. - The company must submit an update to its original plan to regain compliance by November 28, 2025, following a previous submission on September 2, 2025 [6]. - The notice does not have an immediate effect on the listing of the company's common stock on Nasdaq [6]. Operational Challenges - The company is currently unable to provide estimates for operating income or net income for the three- and six-month periods ended September 30, 2025, due to ongoing analysis of a potential goodwill impairment charge [3]. - The company is working diligently to complete and file its Q1 10-Q and Q2 10-Q as soon as possible to regain compliance with Nasdaq listing standards [7]. Company Overview - PetMed Express, Inc. is a pioneer in the direct-to-consumer pet healthcare sector, offering a range of pet health solutions through its brands, including PetCareRx [8]. - The company is licensed across all 50 states and focuses on providing value, convenience, and care to pet owners [8].

We undertake no obligation to update these statements beyond what is required under applicable securities laws. Please refer to the cautionary statements and the risk factors identified in our SEC filings for more detail. Second, presentation slides and today's remarks contain non-GAAP financial measures. Explanations and reconciliations of non-GAAP to GAAP measures may be found in our earnings press release and presentation, available on the Investors section of our website, owenscorning.com. Third, financ ...

Core Insights - CVS Health Corp is a leading player in the healthcare sector, competing with major companies like Walgreens and UnitedHealth Group [1] - RBC Capital upgraded CVS to an "Outperform" rating and raised the price target from $81 to $93 [1][5] Financial Performance - CVS reported third-quarter sales of $102.87 billion, exceeding the consensus estimate of $98.84 billion, representing a 7.8% year-over-year increase [2][5] - The company achieved adjusted earnings per share of $1.60, outperforming the analyst estimate of $1.37, despite a GAAP diluted loss per share of $3.13 due to a $5.7 billion goodwill impairment charge [3][5] - Adjusted operating income increased by 35.8% to $3.46 billion, primarily driven by growth in the Health Care Benefits segment [3] Market Activity - CVS's stock price is currently at $76.81, reflecting a decrease of 4.70% or $3.79, with a trading volume of 6,168,140 shares on the NYSE [4] - Over the past year, CVS's stock reached a high of $85.15 and a low of $43.56 [4] Strategic Initiatives - CVS is preparing to collaborate with EMD Serono on the TrumpRx Fertility Program, set to launch in 2026 [4]

Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to allegations of misleading investors regarding its integration with 3M Company, which has negatively impacted its financial health [2][3]. Financial Performance - On January 10, 2025, Neogen reported a GAAP net income that was significantly negative, primarily due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition [3]. - Neogen cut its fiscal year 2025 revenue and EBITDA guidance following the negative financial disclosures [3]. - On April 9, 2025, Neogen announced a quarterly revenue decline of 3.4% to $221 million, attributing part of this to integration issues, and again revised its FY25 revenue and EBITDA outlook downward [4]. - The company projected capital expenditures of $100 million due to lowered adjusted EBITDA and a pull-forward of integration-related capital expenditures into FY25 [4]. - On June 4, 2025, Neogen expected its EBITDA margin to be in the high teens, a significant drop from the previous quarter's margin of 22% [5]. Stock Performance - Following the January 10, 2025 announcement, Neogen's stock price fell by 5% to close at $12.36 per share [3]. - After the April 9, 2025 announcement, the stock price plummeted by 28% [4]. - By June 4, 2025, the stock price had further declined by 17%, closing at $4.96 per share, marking a total drop of $18.88 per share or 79% from its August 15, 2023 high of $23.84 per share, erasing over $4 billion in market capitalization [5].

Core Viewpoint - Crown Crafts, Inc. has faced significant financial challenges in fiscal 2025, including a substantial net loss and declining profitability, primarily due to a goodwill impairment charge and increased operational costs [2][3][7]. Revenue & Profitability Performance - For Q4 fiscal 2025, Crown Crafts reported net sales of $23.2 million, a 2.9% increase from $22.6 million in the prior year [2] - The company experienced a GAAP net loss of $10.8 million, or $1.04 per diluted share, compared to a net income of $1 million, or $0.10 per diluted share, in the previous year [2] - Gross profit fell 18.8% to $4.2 million, with gross margin narrowing to 18.3% from 23.2% due to unfavorable sales mix and tariff-related costs [2] - For the full fiscal year, revenues decreased by 0.4% to $87.3 million from $87.6 million [3] - Adjusted net income was $1.0 million ($0.10 per share), while GAAP net loss was $(9.4) million, or $(0.90) per diluted share, compared to a net income of $4.9 million, or $0.48 per diluted share in the prior year [3] - Gross profit for the full year fell 7.5% to $21.3 million, with gross margin narrowing to 24.4% from 26.2% [3] Key Business Metrics - The company ended the fiscal year with $0.5 million in cash and cash equivalents, down from $0.8 million the previous year [4] - Inventory was reduced by 6.4% to $27.8 million, reflecting a strategy of higher closeout sales [4] - Marketing and administrative expenses increased by 17% in Q4 to $4.6 million from $3.9 million, largely due to the integration of Baby Boom Consumer Products [4] - Borrowings under the credit facility rose to $18.5 million due to the Baby Boom acquisition [4] Management Commentary - CEO Olivia Elliott described fiscal 2025 as a "transitional year," influenced by persistent inflation and reduced consumer discretionary spending [6] - Strategic initiatives such as acquisitions, e-commerce expansion, and cost containment were emphasized for long-term gains [6] - The company remains optimistic about future positioning, highlighting improved retail partnerships and a streamlined product portfolio [6] Factors Influencing Results - The fourth quarter faced multiple headwinds, including lower margins from closeout sales and increased tariffs totaling $324,000 [7] - The most significant impact came from a $13.8 million goodwill impairment charge due to a decline in market capitalization [7] Guidance and Outlook - Crown Crafts did not provide formal financial guidance but acknowledged significant near-term challenges, particularly related to tariffs [9] - The company is exploring various mitigation strategies and reaffirmed its commitment to growth through product and channel expansion [9] Other Developments - During fiscal 2025, Crown Crafts completed the acquisition of Baby Boom Consumer Products, adding new product lines to its portfolio [10] - The company transitioned its European operations to a distributor model to support long-term sales growth [11] - The redesigned "Love, Stella" doll line gained exposure from a Meghan Markle endorsement, highlighting marketing initiatives [11]

Core Viewpoint - Crown Crafts, Inc. reported a mixed financial performance for the fourth quarter and fiscal year 2025, with increased sales but significant net losses due to various challenges including tariffs and goodwill impairment charges [5][11]. Fourth Quarter Summary - Net sales for the fourth quarter of fiscal 2025 increased by 2.9% to $23.2 million compared to the prior year quarter, driven by the Baby Boom acquisition [6][8]. - Gross margin decreased to 18.3%, a decline of 4.9% from the prior year quarter, attributed to a higher mix of close-out sales and $324,000 in increased tariffs on imports from China [6][8]. - Marketing and administrative expenses rose by 17.0% to $4.6 million, including $77,000 in acquisition costs related to Baby Boom [7][8]. - The company recorded a GAAP net loss of $(10.8) million, or $(1.04) per diluted share, and an adjusted net loss of $(429,000), or $(0.04) per adjusted diluted share, which excludes a goodwill impairment charge of $13.8 million [10][12]. Fiscal 2025 Summary - Total net sales for fiscal 2025 were $87.3 million, essentially flat compared to fiscal 2024 [11][12]. - Gross margin for the year was 24.4%, down 1.8% from fiscal 2024, primarily due to higher rent and increased tariffs [11][12]. - Marketing and administrative expenses increased by 16% to $18.7 million, which included costs associated with the Baby Boom acquisition and the closure of a subsidiary in the UK [12]. - The company reported a GAAP net loss of $(9.4) million, or $(0.90) per diluted share, while adjusted net income was $1.0 million, or $0.10 per adjusted diluted share [12][11]. Goodwill Impairment - A goodwill impairment charge of $13.8 million was recorded due to a decline in the company's market capitalization and the fair values of its reporting units being lower than their carrying values [9][10]. Cash and Inventory Position - At the end of fiscal 2025, the company had $521,000 in cash and cash equivalents, with total inventory at $27.8 million, reflecting a 6.4% decrease compared to the end of fiscal 2024 [13]. Dividend Declaration - The company declared a quarterly cash dividend of $0.08 per share of Series A common stock, to be paid on July 3, 2025 [14]. Company Overview - Crown Crafts, Inc. designs, markets, and distributes a variety of infant, toddler, and juvenile consumer products, and is one of America's largest producers in this sector [16].

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $21.8 million, down from $24.5 million in the prior year, aligning with the higher end of guidance [7][11] - Gross margin decreased to 56% from 60.3% in Q1 2024 [8][15] - Operating loss was $49.7 million compared to a loss of $2.3 million in Q1 2024, primarily due to a goodwill impairment charge [9][10] - Adjusted EBITDA was $800,000, down from $1.6 million in the previous year [10][16] - Cash flow from operations improved to $3 million from $1.4 million in Q1 2024 [17] Business Line Data and Key Metrics Changes - Revenue in The Americas declined 5.4% sequentially and 9.4% year-over-year [12] - European revenue decreased 29% sequentially and 9% year-over-year [13] - APAC revenue increased 6.6% sequentially but was down 17% compared to the prior year [14] Market Data and Key Metrics Changes - The Americas faced slow sales due to budget clarity issues in academic and NIH funding [12] - Europe experienced a decline in cellular and molecular sales, although growth was noted in cell-based testing [13] - APAC market showed signs of improvement but anticipated challenges due to tariff announcements [14] Company Strategy and Development Direction - The company is focusing on expanding adoption of new products while continuing to lower costs, with an expected reduction in operating expenses by an additional $1 million per quarter starting Q2 2025 [26] - New product introductions are categorized into base business, electroporation and bioproduction systems, and MEA/organoid systems, with a strong pipeline of industrial and academic customers [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed concerns about NIH funding and the impact of tariffs on revenue, particularly in China, which constitutes about 10% of total revenue [54] - The company expects Q2 revenue to be in the range of $18 million to $20 million, with gross margin projected between 55% and 57% [26] Other Important Information - A non-cash goodwill impairment charge of $48 million was recorded due to a decrease in market capitalization [10][30] - The company is in the process of refinancing its debt facility, with indications of interest from multiple providers [18][46] Q&A Session Summary Question: Can you elaborate on the impairment charge? - Management explained that the impairment was due to a drop in market capitalization, necessitating a reassessment of goodwill using a DCF approach, leading to a $48 million non-cash charge [30] Question: What about the bioproduction business and CAR T therapy? - Management confirmed that the BTX system is being used by a domestic customer for CAR T therapy development, indicating strong traction in the bioproduction space [31][32] Question: How is the MEA product line performing amid NIH funding uncertainties? - Management noted strong interest in the MEA product line, particularly from academic researchers, despite a slowdown in purchasing processes due to NIH budget cuts [34][35] Question: Will BTX technology compete with MaxSight? - Management indicated that while they could potentially compete, their strategy focuses on early adopters and a razor-razor blade model rather than high-volume applications [40][41] Question: Will animal testing slow down? - Management affirmed that animal testing will continue to be necessary for safety and efficacy verification, although organoids may reduce the need for large animal populations in early testing [43][45] Question: What are the refinancing terms? - Management stated that the refinancing will be more expensive than commercial debt, with a term likely around four to five years [46][49]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $21.8 million, down from $24.5 million in Q1 2024, aligning with the higher end of guidance [7][10] - Gross margin decreased to 56% from 60.3% in the previous year [8][14] - Operating loss was $49.7 million compared to a loss of $2.3 million in Q1 2024, primarily due to a goodwill impairment charge of $48 million [8][10] - Adjusted EBITDA was $800,000, down from $1.6 million in Q1 2024 [15] - Cash flow from operations improved to $3 million from $1.4 million in the prior year [16] Business Line Data and Key Metrics Changes - Revenue in The Americas declined 9.4% year-over-year and 5.4% sequentially [11] - European revenue decreased 29% sequentially and 9% year-over-year [12] - APAC revenue increased 6.6% sequentially but was down 17% compared to the prior year [13] Market Data and Key Metrics Changes - The Americas faced a slowdown attributed to budget clarity issues for academic and NIH funding [11] - European sales were impacted by a lack of seasonal bump and lower CRO sales [12] - APAC market showed slight sequential growth but anticipated challenges due to tariff announcements [13] Company Strategy and Development Direction - Focus on expanding adoption of new products while reducing costs, with an expected reduction in operating expenses by an additional $1 million per quarter starting Q2 2025 [25] - New product introductions include the SOHO telemetry devices and VivaMARS system, targeting both academic and industrial customers [19][20] - Emphasis on bioproduction applications and exploring partnerships for CAR T therapy production [21][31] Management's Comments on Operating Environment and Future Outlook - Management expressed concerns over NIH funding and the impact of tariffs on revenue, particularly in China [25][53] - Positive outlook on the adoption of organoid systems due to government policy changes encouraging alternative testing methods [24][34] - Anticipated Q2 revenue guidance is between $18 million to $20 million, with gross margin expected to be in the 55% to 57% range [25] Other Important Information - Goodwill impairment charge of $48 million was recorded due to a decrease in market capitalization [10][29] - Net debt decreased to $30.8 million, reflecting improved cash flow management [16] Q&A Session Summary Question: Can you elaborate on the impairment charge? - Management explained that the impairment was due to a drop in market cap, necessitating a reassessment of goodwill, leading to a non-cash charge of $48 million [29] Question: What about the bioproduction business and CAR T therapy? - Management confirmed that the BTX system is being adopted by a domestic biotech for CAR T therapy production, indicating strong traction in the market [31] Question: How is the MEA product line performing amid NIH funding uncertainties? - Management noted strong interest in the MEA product line, particularly from academic researchers, despite a slowdown in purchasing processes due to NIH staffing changes [34][45] Question: What are the refinancing plans? - Management indicated that refinancing will be more expensive than commercial rates, with terms likely spanning four to five years [46][48]

Core Insights - DuPont reported strong financial performance in Q1 2025, with a 5% increase in net sales to $3.066 billion and a 6% organic sales growth year-over-year [4][8][9] - The company experienced a significant GAAP loss of $548 million, primarily due to a $768 million non-cash goodwill impairment charge related to the Aramids reporting unit [5][8] - Operating EBITDA increased by 16% to $788 million, with an operating EBITDA margin of 25.7%, reflecting volume benefits and restructuring savings [4][6][9] Financial Performance - Net sales for Q1 2025 were $3,066 million, up from $2,931 million in Q1 2024, marking a 5% increase [4][8] - Organic sales growth was 6%, driven by an 8% increase in volume, partially offset by a 2% decrease in price [9] - GAAP loss from continuing operations was $(548) million, compared to income of $183 million in the prior year, representing a 399% decline [4][8] - Adjusted EPS rose by 30% to $1.03, up from $0.79 in Q1 2024 [4][8] Segment Performance - ElectronicsCo segment net sales increased by 14% to $1,118 million, with an operating EBITDA of $373 million, up 26% [14][20] - IndustrialsCo segment net sales were flat at $1,948 million, with a 6% increase in operating EBITDA to $464 million [16][21] - The ElectronicsCo segment saw a 14% organic sales growth, while IndustrialsCo experienced a 2% organic sales growth [9][14] Cash Flow and Guidance - Cash provided by operating activities from continuing operations was $382 million, down 23% from $493 million in Q1 2024 [4][7] - Transaction-adjusted free cash flow was $212 million, a decrease of 26% compared to the previous year [4][7] - The company maintains its full-year 2025 financial guidance, estimating Q2 2025 net sales of approximately $3.2 billion and adjusted EPS of about $1.05 [17][18] Strategic Developments - DuPont is on track for the spin-off of its Electronics business, named Qnity, scheduled for November 1, 2025 [2][25] - The company is actively managing the impact of tariffs through its global manufacturing footprint and flexible supply chain [2][8]